Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other Non-Current Assets (2019 - 2025)

Keros Therapeutics filings provide 7 years of Other Non-Current Assets readings, the most recent being $1.4 million for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets changed 0.0% to $1.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.4 million, a 0.0% change, with the full-year FY2024 number at $1.4 million, up 20.75% from a year prior.
  • Other Non-Current Assets hit $1.4 million in Q3 2025 for Keros Therapeutics, up from $463000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.4 million in Q3 2024 to a low of $115000.0 in Q1 2021.
  • Median Other Non-Current Assets over the past 5 years was $1.3 million (2021), compared with a mean of $1.1 million.
  • Biggest five-year swings in Other Non-Current Assets: surged 1054.78% in 2021 and later plummeted 61.8% in 2025.
  • Keros Therapeutics' Other Non-Current Assets stood at $1.3 million in 2021, then changed by 0.0% to $1.3 million in 2022, then fell by 9.57% to $1.2 million in 2023, then grew by 20.75% to $1.4 million in 2024, then changed by 0.0% to $1.4 million in 2025.
  • The last three reported values for Other Non-Current Assets were $1.4 million (Q3 2025), $463000.0 (Q1 2025), and $1.4 million (Q4 2024) per Business Quant data.